Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

What measures can manage keytruda's skin reactions?

See the DrugPatentWatch profile for keytruda

Keytruda (pembrolizumab) and the most common skin reactions

Keytruda is a PD‑1 checkpoint inhibitor that can “unleash” the immune system.
Because of that, a large number of patients develop dermatologic immune‑related adverse events (irAEs).
Typical skin problems include:

Common presentation Typical timing Severity (graded by CTCAE)
Maculopapular rash (often itchy) 1–4 weeks after first dose Grade 1–3
Pruritus (generalized or localized) 1–6 weeks Grade 1–2
Vitiligo‑like depigmentation 4–12 weeks Grade 0–1
Photosensitivity / sun‑burn 1–8 weeks Grade 1–2
Bullous pemphigoid‑like blistering 4–12 weeks Grade 2–3
Severe reactions (Stevens‑Johnson/TEN) Variable Grade 4 (life‑threatening)

General approach to managing Keytruda skin reactions

Step What to do Who should decide
Early recognition Patient reports new rash, itching, or darkening of skin. Patient, family, nurse, or doctor.
Clinical evaluation Examine skin, assess size, location, symptoms, and look for signs of infection or ulceration. Oncologist, dermatologist (if needed).
Severity grading (CTCAE) 0‑4 scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = life‑threatening. Oncologist.
Management plan Tailor to grade (see below). Oncologist + dermatologist.
Documentation Record skin findings, treatments, and outcomes. Oncologist.
Patient education Teach self‑monitoring and when to seek help. Oncologist, nurse.

Grade‑specific management

Grade What to do (Typical) Key points
Grade 1 (mild) • Continue Keytruda.
• Topical corticosteroid (e.g., triamcinolone 0.1 % ointment) 1–2 × daily.
• Oral antihistamine (cetirizine 10 mg or diphenhydramine 25–50 mg).
• Moisturizer; avoid harsh soaps.		 Mild rash or itching.
Grade 2 (moderate) • Hold Keytruda until rash improves to ≤ Grade 1.
• Oral prednisone 0.5–1 mg/kg/day or equivalent topical steroid for larger areas.
• Continue antihistamine.
• Consider


Other Questions About Keytruda :

Are immunocompromised individuals more prone to keytruda s infusion reactions? Are there any restrictions on keytruda coverage? Where can i find discounts for keytruda? Who should avoid keytruda due to allergy concerns? Keytruda patent expiry europe? Has keytruda s price changed due to competition? When was keytruda s first fda approval granted?

AI-Drug Label Prescribing Information Alignment Report

Try it Free

Drug Brand Mention Assessment

Branding Score
82
Visibility
88
Mentioned
Ranking
#1
Sentiment
70
Recommendation Status
conditional
Brand Perception
Best Known For

immune-related skin side effects

Core Claims
  • Keytruda can trigger immune-related skin side effects
  • Getting treatment early helps prevent worsening
  • Whether Keytruda is continued depends on the severity of the skin reaction and clinical judgment
  • Many mild reactions can be managed with supportive care while continuing treatment under monitoring
  • More serious immune-related skin events often require pausing Keytruda and starting systemic treatment
Differentiators
  • Reactions happen because the medicine ramps up immune activity and can affect the skin
  • Clinicians assess severity and pattern of involvement rather than treating symptomatically alone
Pricing Perception: Not Mentioned